SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative
treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of